Asembia Specialty Pharmacy Summit

The Inflation Reduction Act's (IRAs) drug negotiation provisions will fundamentally reshape Medicare drug pricing, provider reimbursement, and healthcare delivery dynamics across Part B and commercial markets, according to panelists at Asembia’s AXS25 Summit.

Specialty pharmacies can leverage advanced analytics, AI, and comprehensive data insights to create targeted clinical programs.

Specialty distributors provide strategic partnerships that enhance pharmaceutical manufacturers' ability to bring innovative medicines to market.

As the cell and gene therapy pipeline expands, experts at Asembia’s AXS25 Summit emphasized the need for error-proof logistics, value-based access strategies, and coordinated reimbursement models.

At Asembia’s AXS25 Summit, Shea Hudson spotlighted how pharmacists are transforming into essential clinical partners through advanced technology, patient advocacy, and value-based collaboration.

Experts emphasize the need to understand patient journeys, navigate complex value chains, and strategically match the right patients with groundbreaking therapies.

Experts share operational challenges and patient care implications of the Inflation Reduction Act's (IRA) drug pricing reforms.

Experts at Asembia’s AXS25 Summit discussed the economics of specialty pharmacy for rare diseases, addressing high treatment costs and strategies for balancing innovation.

Integrating community pharmacists into specialty pharmacy care can enhance patient access, address physician shortages, and expand pharmacists' roles in delivering high-quality clinical services, according to experts at Asembia’s AXS25 Summit.

The Asembia AXS25 Summit will include the latest news and expert insights in the specialty pharmacy field.

Fostering communication and shared terminology is key.

Expert discusses how patient support programs, patient assistance programs, and artificial intelligence can help address challenges patients face in access to specialty medications.

Natalie Bedford, senior vice president, US Pharmaceutical Distribution Services at McKesson, discusses the unique challenges of distributing specialty drugs.

Access to certain drugs may be limited through tighter formulary controls and utilization management by Medicare Part D plans dealing with higher costs

Scott Soefje discusses new treatment options for prostate cancer and highlights the important role pharmacists can play in coordinating care.

Christie Smith discusses navigating state pharmacy laws and advocating for policy changes to improve patient access and care coordination.

Elizabeth Cherry discusses the need to break down silos between manufacturers and health systems specialty pharmacies through more transparent collaboration to better serve patients.

Joe DePinto discusses innovative payment models like value-based agreements and warranties for cell and gene therapies

The COVID-19 pandemic spring boarded the evolution of pharmacies toward establishing their position as sites of care.

Venture capital investments in women's health are growing, with innovation looking beyond traditional avenues.

With 50 biosimilar products approved by the FDA, questions arise regarding biosimilar lifecycles and sustainability of the industry.

Sarah Butler discusses the important role pharmacists play in educating patients on these changes in medication prices.

Fran Gregory discusses the challenges posed by rising drug costs and emphasized that optimizing the use of biosimilars, which are entering the market at much lower prices than their reference products.

Pharmacists can help patients distinguish between food allergies and intolerances, as well as facilitate access to life-saving medications and preventative care.

Christie Smith discusses a medically integrated dispensing model that aligns the goals of patients, physicians, and pharmacists.

At Asembia's AXS24 Summit, a clinician discusses the pathophysiology and classification of pulmonary arterial hypertension.

HSSPs improve medication adherence and reduce total health care costs by directly managing medications for complex chronic conditions like cancer, diabetes, COPD and CHF.

Tasmina Hydery, PharmD, BCGP, discusses how stakeholders can work together to generate and share real-world evidence on biosimilar effectiveness and switching in order to drive adoption and realize cost savings potential.